All the above-mentioned studies suggest that decreased BDNF/TrkB signaling is strongly involved in the pathogenesis of AD, and the development of methods to increase BDNF in patients’ brains is expected to lead to treatment of the disease. This evidence concerns the gene NTRK2 and Alzheimer disease.